Kenza Health Hub logoGet Started
1 May 2026Injectable drugsSource update: March 2024

Amphotericin B Conventional Injectable: Dosing and Safety

Conventional amphotericin B guidance for cryptococcal meningitis induction and severe systemic fungal infections, with major renal-toxicity precautions.

Also searched as

Amphotericin B conventional
Prescription under medical supervision

Source reviewed

March 2024

Guide category

Injectable drugs

Safety boundary

Prescription medicine information for clinician-guided use.

Kenza Health Hub presents this medicine page as structured health education. Check dose, route, interactions, pregnancy or breast-feeding considerations, and local protocol with a qualified clinician or pharmacist. Read our medical editorial policy.

This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.

Therapeutic action

Antifungal.

Indications

  • Cryptococcal meningitis induction phase, in combination with flucytosine or fluconazole.
  • Severe histoplasmosis or penicilliosis.

Forms and strengths, route of administration

  • Powder for injection, in 50 mg vial, dissolved in 10 ml water for injection to obtain a concentrated solution containing 5 mg/ml.
  • The concentrated solution must be diluted in 500 ml of 5% glucose to obtain a solution containing 0.1 mg/ml, for slow IV infusion.

Dose

  • Child and adult: 0.7 to 1 mg/kg once daily over 4 to 6 hours depending on tolerance.

Duration

  • Cryptococcal meningitis: one week if in combination with flucytosine, or 2 weeks if in combination with fluconazole.
  • Histoplasmosis: 1 to 2 weeks.
  • Penicilliosis: 2 weeks.

Contra-indications, adverse effects, precautions

  • Due to numerous and potentially severe adverse effects, patients should be kept under close surveillance.
  • Administer with caution to patients with renal impairment.
  • May cause intolerance reactions during administration, local thrombophlebitis, allergic reactions, muscle or joint pain, cardiovascular disorders, neurologic disorders, haematological or hepatic disorders, and renal-function disturbances including hypokalaemia and hypomagnesiemia.
  • Avoid combination with drugs causing hypokalaemia, nephrotoxic drugs, digoxin, and zidovudine.
  • To prevent renal toxicity, administer 500 ml to 1 litre of 0.9% sodium chloride or Ringer lactate prior to each infusion.
  • Monitor serum creatinine and, if possible, serum potassium throughout treatment.
  • If renal function deteriorates, increase preventive hydration or stop treatment, then resume at the lowest effective dose or on alternate days after improvement.
  • Pregnancy: check for renal dysfunction in the neonate if administered during the last month of pregnancy.
  • Breast-feeding: avoid, except if vital.
  • Only use 5% glucose for administration and do not add other drugs in the infusion bottle or bag.

Source

MSF Essential drugs practical guidelines (January 2026)

This page combines source-derived medicine reference sections with Kenza editorial context, while leaving out the Storage and Remarks sections from the source batch.

Rate this guide

Be the first to rate this guide.